Incyte (INCY) Up 2.6% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]
Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Janus Kinase (JAK) Inhibitor Pipeline Market Insights Report 2025: Comprehensive Review of 50+ Companies and Respective 55+ Drugs [Yahoo! Finance]
JAK Inhibitors Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight [Yahoo! Finance]